Agendia will launch a next-generation sequencing test in the EU to determine the chances of metastasis in breast cancer patients. Agendia, a US-Dutch biotech specializing in personalized medicine and molecular diagnostics, has obtained CE marking for the MammaPrint BluePrint Kit, a diagnostic ...
This awesome article A Personalized Genetic Test for Breast Cancer Arrives in Europe appeared first on Labiotech.eu. Be kind and don't copy it without asking ;)
Original Article: A Personalized Genetic Test for Breast Cancer Arrives in Europe
NEXT ARTICLE